MaxCyte, Inc. (MXCT)
$0.99-1.98%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $106M
- Beta
- 1.53
- P/E (TTM)
- -3.26
- Short % float
- 1.12%
- Days to cover
- 3.1
- SI change
- -6.9%
- 1W
- -8.33%
- 1M
- -14.66%
- vs SPY 1W
- -8.76%
- vs SPY 1M
- -16.72%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 5
- GROWTH
- 41
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-12.6%
REV YoY-
ROE-21.0%
EPS YoY-
ROA-19.3%
GROSS79
OP-112
NET-115
[VALUATION]
P/E TTM-3.26
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B0.73
P/FCF-
EV/EBITDA-3.67
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E10.87
ALTMAN Z-
CURR RATIO12.26
ND/EBITDA-
BETA1.53
Company news
FAQ
- What is LOPJLB’s current signal on MXCT?
- LOPJLB’s latest quantitative signal on MaxCyte, Inc. (MXCT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MXCT in?
- MaxCyte, Inc. (MXCT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MaxCyte, Inc. (MXCT) do?
- MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-…